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with a risk factor, (heart and respiratory failure) the res-
piratory infection probability is 4.3%, inducing hospital-
izations in 37% of cases. RESULTS: Direct costs were
calculated as the sum of costs due to medication, consul-
tations, hospitalization and respiratory physiotherapy.
The impact of indirect cost should also be taken into con-
sideration. Our estimation evaluated them four times in-
ferior to those due to influenza. With regards to the risk
of hospitalization (1%–3% or 5%), the average cost of
RSV infection varies, according to a societal perspective,
from 750 to 1103 Euros. CONCLUSION: The annual fi-
nancial burden of RSV disease from the payer perspective
would be between 306 to 612 millions Euros. This an-
nual figure represents a third of the cost allocated to in-
fluenza, which justifies the efforts of research in view of
making emerge a vaccine against the RSV.
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OBJECTIVES: Asthma bronchiale (AB) and chronic bron-
chitis (CB) are common chronic disorders with high rates
of prevalence. We performed a cost of illness study that
aimed to assess the economic burden of these disorders in
Germany. To the best of our knowledge, we used the first
time data for entire Germany, in contrast with the few
previous studies. METHODS: We obtained in a retro-
spective analysis secondary data from governmental insti-
tutions as well as from pharmaceutical industry. Re-
source use was based on 1996 schedules and costs were
estimated in 1996 DM. We chose the cost perspective of
sickness funds to estimate direct costs. The human capital
approach was applied for the calculation of indirect
costs. RESULTS: Total estimated costs were DM 5.81
billion related to AB, and DM 20.17 billion related to
CB. We did not include outpatient physician services in
the calculation of direct costs in lack of adequate data.
Therefore, direct costs represented only 33% and 22% of
total estimated costs, respectively. The most important
cost driver of direct costs was outpatient prescribed med-
icines, followed by hospitalization. Outpatient prescribed
medicines accounted for 55% and 63% of the direct
costs, respectively. Of the indirect costs of AB 43% were
associated with early retirement. Loss of work was with
75% by far the largest single cost driver of indirect costs
due to CB. CONCLUSIONS: Findings from this study
for Germany show the evident importance of outpatient
prescribed medicines as cost driver of direct costs of AB
as well as of CB. Furthermore, this study underlines the
major role of loss of work concerning indirect costs of
CB. The data suggest that therapeutic progress and cessa-
tion of smoking can provide distinctive savings of direct
costs and even more of indirect costs of AB and CB.
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OBJECTIVE: To determine the appropriateness of using
prescription treatment to measure asthma severity in a
retrospective claims database. METHODS: All patients
within PharMetric’s Integrated Outcomes Database pos-
sessing a diagnosis of asthma (ICD-9-CM  493) and a
prescription claim for an asthma medication during 1997–
1998, were eligible for study inclusion. Patients with less
than 12 months of enrollment following the initial asthma
diagnosis, or a diagnosis of chronic obstructive pulmo-
nary disease (COPD) or cystic fibrosis (CF) were ex-
cluded from the analysis. Patients were assigned into se-
verity levels based on the combination of asthmatic
regimens received during the study period: Level 1 
Short Acting Beta Agonist (SABA) Only; Level 2  one
controller medication (Mast Cell Stabilizer, Inhaled Corti-
costeroid, or Leukotriene Modifying Agent); Level 3  2
Controllers (above list  Long Acting Beta Agonis); Level
4  3 or more controllers (above list  Long Acting Beta
Agonist). Patient demographics, asthma-specific charges,
and comorbid conditions were captured for each patient
during the study period. RESULTS: 124,076 patients met
the inclusion criteria. The mean age was 23.6 years (SD 
19.6), and 53.0% were female. Over half (50.5%) of pa-
tients were in Level 1, while only 0.9% were in Level 4.
Mean age and percentage of females increased with in-
creasing severity. The mean annual asthma-specific charge
per patient was $675.73 (SD  $1992.10), and ranged
from $379 for Level 1 patients to $1,414 for Level 4 pa-
tients. Prevalence of diabetes, hypertension, and depres-
sion increased with increasing severity, while upper-
respiratory and lower-respiratory infections decreased.
CONCLUSION: The use of treatment regimen appears
to be a viable alternative for measuring severity of asthma
in retrospective analyses, however further research is needed.
ARTHRITIS/OSTEOPOROSIS
PAO1
COST-EFFECTIVENESS ANALYSIS OF NSAIDS 
VS COX-2 SPECIFIC INHIBITORS AND NSAIDS 
WITH CO-TREATMENTS TO PREVENT GI 
TOXICITY IN THE TREATMENT OF RA
Yun HR1, Corzillius M2, Kim SY1, Bae SC1
1The Hospital for Rheumatic Diseases, Hanyang University, 
Seoul, Republic of Korea; 2Department of Internal Medicine, 
Christian-Albrechts-University of Kiel, Kiel, Germany
BACKGROUNDS: Nonsteroidal anti-inflammatory drugs
(NSAIDs) are used in nearly every patient with rheuma-
toid arthritis (RA) but their use can be associated with
